Abstract
Abstract
Background
Moyamoya disease (MMD) is a significant cause of childhood stroke and transient ischemic attacks (TIAs). This study aimed to assess the safety and efficacy of remote ischemic conditioning (RIC) in children with MMD.
Methods
In a single-center pilot study, 46 MMD patients aged 4 to 14 years, with no history of reconstructive surgery, were randomly assigned to receive either RIC or sham RIC treatment twice daily for a year. The primary outcome measured was the cumulative incidence of major adverse cerebrovascular events (MACEs). Secondary outcomes included ischemic stroke, recurrent TIA, hemorrhagic stroke, revascularization rates, and clinical improvement assessed using the patient global impression of change (PGIC) scale during follow-up. RIC-related adverse events were also recorded, and cerebral hemodynamics were evaluated using transcranial Doppler.
Results
All 46 patients completed the final follow-up (23 each in the RIC and sham RIC groups). No severe adverse events associated with RIC were observed. Kaplan–Meier analysis indicated a significant reduction in MACEs frequency after RIC treatment [log-rank test (Mantel–Cox), P = 0.021]. At 3-year follow-up, two (4.35%) patients had an ischemic stroke, four (8.70%) experienced TIAs, and two (4.35%) underwent revascularization as the qualifying MACEs. The clinical improvement rate in the RIC group was higher than the sham RIC group on the PGIC scale (65.2% vs. 26.1%, P < 0.01). No statistical difference in cerebral hemodynamics post-treatment was observed.
Conclusions
RIC is a safe and effective adjunct therapy for asymptomatic children with MMD. This was largely due to the reduced incidence of ischemic cerebrovascular events.
Graphical abstract
Funder
The National Natural Science Foundation of China
Publisher
Springer Science and Business Media LLC
Reference43 articles.
1. Scott RM, Smith ER. Moyamoya disease and moyamoya syndrome. N Engl J Med. 2009;360:1226–37.
2. Baba T, Houkin K, Kuroda S. Novel epidemiological features of moyamoya disease. J Neurol Neurosurg Psychiatry. 2008;79:900–4.
3. Zhang D, Huang L, Huang Z, Zhou Q, Yang X, Gu H, et al. Epidemiology of moyamoya disease in China: a nationwide hospital-based study. Lancet Reg Health West Pac. 2022;18:100331.
4. Shang S, Zhou D, Ya J, Li S, Yang Q, Ding Y, et al. Progress in moyamoya disease. Neurosurg Rev. 2020;43:371–82.
5. You TY, Dong Q, Cui M. Emerging links between cerebral blood flow regulation and cognitive decline: a role for brain microvascular pericytes. Aging Dis. 2023;14:1276–91.